# Product Summary

| Product Code | Product Name | Modality Name | Product Type | Therapeutic Area | Current Phase | Project Status | Expected Launch Year | Lead Indication | Mechanism Of Action | Short Description | Patient Population | Dosage Form | Route Of Administration | Base Technology | Primary Packaging | Ppq Status | Critical Path Item | Ppq Details | Biel Category | Timeline Variance Days | Timeline Variance Baseline | Ds Volume Category | Dp Volume Category | Ds Suppliers | Dp Suppliers | Device Partners | Operational Risks | Timeline Risks | Supply Chain Risks | Regulatory Details | Submission Status | Launch Geography | Process Template Name |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BI 1015550 | Nerandomilast | Small Molecule | NME | Respiratory (IPF; PPF in Zulassung) | Approved/Launched (US, 09-Oct-2025, IPF) | On Track | 2025 | Idiopathic Pulmonary Fibrosis (IPF) | An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). | Oraler PDE4B-Inhibitor, der den FVC-Rückgang bei IPF signifikant verlangsamt (Phase-3). |  | Tablet | Oral | Twin Screw | Blister; Bottle | Ongoing |  | DS: ING=ongoing ¦ DP: ING_SoL=ongoing | 3A | -10 | AD 2024 | Low (10 - 1,000 kg) | Medium (10 - 100 million PCS) | ING @Ingelheim (qualified) | ING_SoL @Ingelheim (launch_ready); Koropi (transfer_ongoing) |  | HIGH: 1 | MED: 1 |  | IPF: 2 designations | Submitted | US; China |  |
| BI 1015550_MYO | Nerandomilast | Small Molecule |  | Immunology |  |  | 2030 | Myositis | An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). | Line extension of Nerandomilast for Myositis indication. |  | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1015550_PED | Nerandomilast | Small Molecule |  | Respiratory | Pre-Clinical | On Track | 2030 | Pediatric Pulmonary Fibrosis | An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). | Pediatric line extension of Nerandomilast for pulmonary fibrosis. Uses different manufacturing process (Fluid Bed, outsourced to Almac). |  | Pediatric formulation | Oral | Fluid Bed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1015550_PPF | Nerandomilast | Small Molecule |  | Respiratory | Phase III | On Track | 2026 | Progressive Pulmonary Fibrosis | An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). | Line extension of Nerandomilast for Progressive Pulmonary Fibrosis. Phase III development. |  | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1015550_SSC | Nerandomilast | Small Molecule |  | Immunology | Phase II | On Track | 2030 | Systemic Sclerosis | An oral, preferential inhibitor of phosphodiesterase 4B (PDE4B). | Line extension of Nerandomilast for Systemic Sclerosis. Phase II development. |  | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1291583 | Verducatib | Small Molecule | NME | Respiratory; Immunology | Phase III | Delayed | 2029 | Non-Cystic Fibrosis Bronchiectasis (NCFBE) | Cathepsin C (CatC) inhibitor. | A CatC inhibitor for inflammatory lung conditions, targeting neutrophil serine proteases activation. |  | Tablet | Oral | Direct compression + Film-coating | Blister; Bottle |  |  |  | 3B | 135 | AD 2024 | Low (10 - 1,000 kg) | Medium (10 - 100 million PCS) | ING (ongoing) | ING_SoL (ongoing) |  | HIGH: 3 |  |  | NCFBE: 1 designation |  |  |  |
| BI 1291583_PED | Verducatib PED | Small Molecule |  | Respiratory; Immunology | Pre-Clinical |  | 2031 | Non-Cystic Fibrosis Bronchiectasis Pediatric | Cathepsin C (CatC) inhibitor. | Pediatric line extension of Verducatib for Non-Cystic Fibrosis Bronchiectasis in pediatric populations. | Pediatric patients with Non-Cystic Fibrosis Bronchiectasis | Pediatric formulation | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1356225 |  | Small Molecule | NME | Mental Health (Impulsivity in Substance Use Disorder) | Phase I | On Track | 2034 | Impulsivity/Substance Use Disorder (SuD) / Obesity | GOAT (Ghrelin O-acyltransferase) inhibitor. | Oraler GOAT-Inhibitor zur Reduktion von Impulsivität bei Opioid-Use-Disorder; Präzisionspsychiatrie-Ansatz. |  | Film-coated tablets (2.5/10 mg); Powder for oral solution (20 mg) | Oral | Solid oral DP (film-coated tablet; PfOS verfügbar) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1358894 |  | Small Molecule | NME | Mental Health | Phase II | Discontinued |  | Post-Traumatic Stress Disorder (PTSD) | TRPC4/5 inhibitor. | A TRPC4/5 inhibitor targeting ion channels implicated in mood and stress-related disorders like PTSD. |  | Tablet | Oral | Fluid Bed | Blister; Bottle |  |  |  | 3A | 0 | AD 2024 | High (> 10 tn) | High (> 100 million PCS) | ING (qualified); BDC @Biberach (qualified) | ING_SoL @Ingelheim (qualified) |  |  |  |  |  |  |  |  |
| BI 1569912 |  | Small Molecule | NME | Mental Health | Phase II | Discontinued |  | Major Depressive Disorder (MDD) - adjunctive therapy | An oral, NMDA subunit 2b-selective negative allosteric modulator (NR2B NAM). | An oral NR2B NAM designed to rapidly relieve depressive symptoms in MDD without dissociative side effects. |  | Tablet | Oral |  | Blister; Bottle |  |  |  | 3B | 0 | AD 2024 |  |  |  |  |  | MED: 1 |  |  |  |  |  |  |
| BI 1584862 | Not disclosed | Small Molecule | NME | Eye Health | Phase II | On Track | 2032 | Geographic Atrophy (GA) | PAFR (Platelet-Activating Factor Receptor) antagonist. | An oral PAFR antagonist for Geographic Atrophy (GA). |  | Film-coated tablet (10/20/50 mg) | Oral | Direct Compression | Blister; Bottle |  |  |  | 3A | 0 | AD 2024 |  |  | EACD (ongoing) | EACD (ongoing) |  |  |  |  |  |  |  |  |
| BI 1703880 |  | Small Molecule | NME | Oncology | Phase I | On Track | 2032 | Non-Small Cell Lung Cancer (NSCLC) | Systemic 'Second-Generation' STING agonist. | Systemic STING agonist in Phase I combination trial for a broad range of solid tumors. |  | Injectable | Injectable (SFInj) | Synthetisches niedermolekulares Molekül | Vial |  |  |  | 3B | 0 | AD 2024 | Low (10 - 1,000 kg) | Very Low (< 1 million PCS) | C(D)MO (ongoing) | C(D)MO (ongoing) |  |  |  |  |  |  |  |  |
| BI 1810631 | Zongertinib | Small Molecule | NME | Oncology | Approved/Launched (US, Accelerated Approval 08-Aug-2025) | On Track | 2026 | Non-Small Cell Lung Cancer (NSCLC) with HER2 alterations. | Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI). | An irreversible, HER2-selective TKI designed to block uncontrolled cell production in HER2-driven cancers like NSCLC. | Patients with HER2-driven cancers / advanced solid tumors with HER2 gene alterations. | Tablet | Oral | Spray Dried Dispersion (SDD) + Film-Coated Tablet (FCT) | Bottle | Completed | OPS | DS: Cambrex=completed, Alphora=ongoing ¦ DP: Hovione=completed, ING=completed | 3A | 0 | AD 2024 | Low (10 - 1,000 kg) | Low (1 - 10 million PCS) | Cambrex (qualified); Alphora (ongoing) | Hovione (qualified); ING (qualified) |  | HIGH: 1 | MED: 1 |  | NSCLC: 2 designations | Submitted | US |  |
| BI 1810631_BC1 | Zongertinib | Small Molecule |  | Oncology |  |  | 2029 | Breast Cancer (Third-Line and Beyond) | Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI). | Line extension of Zongertinib for third-line and beyond breast cancer with HER2 alterations. | Patients with HER2-driven breast cancer | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1810631_BC2 | Zongertinib | Small Molecule |  | Oncology |  |  | 2032 | Breast Cancer (Second-Line) | Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI). | Line extension of Zongertinib for second-line breast cancer with HER2 alterations. | Patients with HER2-driven breast cancer | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1810631_GC | Zongertinib | Small Molecule |  | Oncology |  |  | 2031 | Gastric Cancer (Second-Line) | Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI). | Line extension of Zongertinib for second-line gastric cancer with HER2 alterations. | Patients with HER2-driven gastric cancer | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1810631_NSCLC2 | Zongertinib | Small Molecule |  | Oncology | Phase III |  | 2031 | Non-Small Cell Lung Cancer (Adjuvant) | Irreversible, HER2-selective Tyrosine Kinase Inhibitor (TKI). | Line extension of Zongertinib for adjuvant treatment of NSCLC with HER2 alterations. | Patients with HER2-driven NSCLC in adjuvant setting | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1815368 |  | Small Molecule | NME | Eye Health (DME-Fokus in laufender Entwicklung) | Phase II | On Track | 2032 | Wet AMD prevention (nAMDp) | PKK (Plasma Kallikrein) inhibitor. | Oraler PKK-Inhibitor zur Behandlung des diabetischen Makulaödems (DME). |  | Tablet | Oral |  | Blister; Bottle |  |  |  | 2 | 0 | AD 2024 |  |  | ING @Ingelheim (ongoing) |  |  |  |  |  |  |  |  |  |
| BI 1815368_NAMD | Not disclosed | Small Molecule |  | Ophthalmology |  |  | 2035 | nAMD Prevention | Plasma Kallikrein (PKK) inhibitor - inhibits PKK to reduce vascular permeability and inflammation in retinal diseases. | Line extension of PKK inhibitor for prevention/adjunct treatment of neovascular age-related macular degeneration. | Patients at risk for or with early nAMD | Powder for Oral Solution | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 1819479 |  | Small Molecule | NME | Respiratory; Immunology | Phase II | On Track | 2031 | Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPF) | Lysophospholipase inhibitor / Autotaxin (ATX) inhibitor. | An Autotaxin (ATX) inhibitor targeting the generation of lysophosphatidic acid (LPA) involved in fibrosis. |  | Tablet | Oral | Fluid-bed-Granulation + Endmischung, Kompression, Film-Coating | Blister; Bottle |  |  |  | 4 | 0 | AD 2024 | Low (10 - 1,000 kg) | Medium (10 - 100 million PCS) |  | Corden (ongoing) |  |  |  |  |  |  |  |  |
| BI 1821736 |  | Gene Therapy | NBE | Oncology | Discontinued | Discontinued |  | HNSCC; Melanoma | VSV-GP-CD80-Fc OV (Oncolytic Virus). This is a second-generation oncolytic virus, likely with enhanced immune-stimulatory properties via the CD80-Fc component. | A second-gen oncolytic virus with enhanced immune-stimulation via a CD80-Fc component for HNSCC and Melanoma, administered intratumorally and intravenously. |  | Injectable | Intratumoral (i.t.) und Intravenös (i.v.) | Viral (VSV-GP-CD80-Fc platform) | Vial |  |  |  | NCY | 0 | AD 2024 | High (> 30 12k runs) | Very Low (< 1 million PCS) | Lonza (ongoing) | Lonza (ongoing) |  |  |  |  |  |  |  |  |
| BI 1831169 |  | Gene Therapy | NBE | Oncology | Phase I | On Track | 2034 | Pancreatic Ductal Adenocarcinoma (PDAC); HNSCC; Melanoma | VSV-GP OV (Vesicular Stomatitis Virus - Glycoprotein Oncolytic Virus). | An oncolytic virus gene therapy for solid tumors like PDAC, HNSCC, and Melanoma, administered intratumorally and intravenously. |  | Injectable | Intratumoral (i.t.) und Intravenös (i.v.) | Viral (VSV-GP platform) | Vial |  |  |  | NCY | 0 | AD 2024 | High (> 30 12k runs) | Very Low (< 1 million PCS) | Lonza (ongoing) | Lonza (ongoing) |  |  |  |  |  |  |  |  |
| BI 1839100 |  | Small Molecule | NME | Respiratory | Phase II | On Track |  | IPF/PPF cough | TRPA1 inhibitor. | TRPA1-Inhibitor zur Hustenreduktion bei IPF/PPF (zusätzlich krankheitsbezogene Endpunkte in Evaluierung). |  | Tablet | Oral |  | Blister; Bottle |  |  |  | 3A | 0 | AD 2024 |  | Medium (10 - 100 million PCS) | ING @Ingelheim (ongoing) | ING_SoL @Ingelheim (ongoing) |  |  |  |  |  |  |  |  |
| BI 3000202 |  | Small Molecule | NME | Immunology | Phase I | On Track | 2032 | Systemic Sclerosis (SSc) / IFN (Interferonopathies) | cGAS inhibitor. | Oraler cGAS-Inhibitor für SSc und monogene Interferonopathien; potenziell krankheitsmodifizierend. |  | Film-coated tablets (1/10/25/50 mg) | Oral |  | Blister; Bottle |  |  |  |  | 0 | AD 2024 |  |  | C(D)MO (ongoing) | C(D)MO (ongoing) |  |  |  |  |  |  |  |  |
| BI 3000202_DF4 | Not disclosed | Small Molecule |  | Immunology / Autoinflammatory Diseases |  |  | 2032 | Type I Interferonopathy dF4 | cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling. | Line extension of cGAS inhibitor for type I interferonopathy dF4 indication. | Patients with type I interferonopathy dF4 | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3000202_SSC | Not disclosed | Small Molecule |  | Immunology |  |  | 2035 | Systemic Sclerosis | cGAS inhibitor - inhibits cyclic GMP-AMP synthase, reducing type I interferon signaling and fibrosis. | Line extension of cGAS inhibitor for Systemic Sclerosis. | Patients with Systemic Sclerosis | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3006337 | Not disclosed; Partner-Alias: YH25724 | Recombinant Proteins | NBE (Biologic) | Cardiovascular-Renal-Metabolic (CRM) | Discontinued | Discontinued |  | MASH | GLP-1/FGF21 agonist. | Langwirksames hyFc-basiertes duales GLP-1/FGF21-Fc-Fusionsprotein für MASH. |  | Subkutane Injektion (wöchentlich) | Subkutan | hyFc (IgD/IgG4)-Fc-Fusionsplattform | Bulk_PFS (Bulk Pre-filled Syringe) |  |  |  | 2 | 0 | AD 2024 | Very Low (< 5 12k runs) | Very Low (< 1 million PCS) | C(D)MO (ongoing) | C(D)MO (ongoing) |  |  |  |  |  |  |  |  |
| BI 3009947 |  | Small Molecule | NME | Immunology | Pre-Clinical | Discontinued |  | Systemic Sclerosis (SSc); IFN (Interferonopathies) | STING inhibitor. | STING inhibitor for systemic sclerosis and interferonopathies |  | Orale Darreichungsform geplant (exakte Formulierung TBD) | Oral |  |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3018078 / BI 3024308 |  | Gene Therapy | NBE (Biologic) | Oncology | Phase Ib | On Track |  | Colorectal Cancer (CRC) | Heterologes Prime-Boost (ATP128 → VSV-GP128) zur Induktion tumor-spezifischer T-Zell-Immunität; in Kombination mit PD-1-Blockade (Ezabenlimab). | Therapeutischer Protein-Impfstoff (ATP128) + VSV-GP128 als Boost; Evaluierung bei MSS Stadium IV CRC in Kombi mit Ezabenlimab. |  | Injectable | Parenteral (kombinationsabhängig) | KISIMA® rekombinantes Protein-Impfstoff-Platform + VSV-GP viraler Vektor |  |  |  |  | 4 | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3031185 |  | Small Molecule | NME | Mental Health | Pre-Clinical | On Track | 2034 | Impulsivity | mGluR4 NAM (Negative Allosteric Modulator). | An mGluR4 Negative Allosteric Modulator for Impulsivity. |  | Orale solide Darreichungsform (geplant) | Oral |  | Blister; Bottle |  |  |  | 3A | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3032950 |  | Monoclonal Antibody | NBE | Immunology | Phase II | On Track | 2034 | Crohn's Disease (CD) | TREM-1 antagonist. | TREM-1 antibody for Ulcerative Colitis (induction i.v., maintenance s.c.); IBD program, CD in evaluation. |  | Intravenöse Infusion (Induktion) und subkutane Injektion (Erhaltung) | IV (Induktion), SC (Erhaltung) |  | PFS (Pre-filled Syringe) |  |  |  | 2 | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3034701 | Not disclosed | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase I | On Track | 2032 | Obesity (Overweight/Obesity BMI ≥27 kg/m²) | Triple agonist targeting GLP-1R, GIPR, and NPY2R - simultaneous activation of three receptors involved in appetite regulation and energy homeostasis for weight management. Long-acting peptide therapeutic. | Long-acting triple agonist peptide (GLP-1R/GIPR/NPY2R) for obesity. Phase I study evaluating safety, tolerability, and pharmacokinetics in people with overweight/obesity. | Adults with overweight or obesity (BMI ≥27 kg/m²) | Long-acting injectable formulation (specific device not disclosed) | Subcutaneous (presumed, typical for long-acting peptides) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Obesity: 1 designation |  |  |  |
| BI 3706674 |  | Small Molecule | NME | Oncology | Phase I | On Track |  | Gastric Cancer (GC); Esophageal Cancer (EC); Gastroesophageal Junction Cancer (GEJC); Pancreatic Ductal Adenocarcinoma (PDAC) | Nicht-kovalenter Multi-KRAS-Inhibitor, der GDP-gebundenes KRAS (wt-amp & mehrere Mutanten, inkl. G12V) bindet. | Monotherapie-Entwicklung bei KRAS-WT-Amplifikationen (GC/EC/GEJ) und KRAS-G12V (u.a. PDAC). |  | Tablet | Oral |  | Blister; Bottle |  |  |  | 3A | 0 | AD 2024 |  |  | EACD (ongoing) | EACD (ongoing) |  | HIGH: 1 |  |  |  |  |  |  |
| BI 3720931 |  | Gene Therapy | NBE | Cystic Fibrosis (Respiratory) | Phase I/II (Lenticlair-01 FIH started Nov 2024) | Active | 2032 | Cystic Fibrosis (CF) | Third-generation, self-inactivating lentiviral vector therapy for inhaled CFTR gene delivery. | Inhaled lentiviral gene therapy for cystic fibrosis. |  | Nebulizer solution for inhalation | Inhalation (nebulized) | Third-generation self-inactivating lentiviral vector |  |  |  |  | NCY | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3731579 |  | Small Molecule | NME | Inflammation & Respiratory / Respiratory (IPF/PPF) | Pre-Clinical | Discontinued | 2033 | IPF/PPF prevention (IPF/PPFp) | NOX4 inhibitor. | Oraler NOX4-Inhibitor zur Progressionsverlangsamung bei IPF/PPF (präklinisch). |  | film-coated tablet (Tablette) | oral | Spray-Dried Dispersion (HPMCAS) → Direktverpressung/Filmbeschichtung | Blister; Bottle |  |  |  | 3A | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3776528 |  | Small Molecule | NME | Mental Health – Cognitive impairment in PSD/Schizophrenia | Phase I (laufend) | On Track |  | Cognitive Impairment Post-Stroke Depression (CI PSD) | SSTR4 agonist. | Oraler SSTR4-Agonist zur Behandlung kognitiver Beeinträchtigung in PSD/SCZ-Spektrum. |  | Capsules (1-40 mg; mit Placebo-Match) | Oral | Orale Kapseln |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3793898 |  | Small Molecule | NME | Mental Health | Pre-Clinical (post-SoD) | On Track |  | Cognitive Impairment Associated with Schizophrenia (CIAS) | mGluR3 PAM (Positive Allosteric Modulator). | An mGluR3 Positive Allosteric Modulator for Cognitive Impairment Associated with Schizophrenia (CIAS). |  |  |  |  |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3794407 |  | Small Molecule | NME | Inflammation & Respiratory (I&R) | Pre-Clinical | Discontinued |  | Systemic Sclerosis (SSc) | cGAS inhibitor. | Oraler cGAS-Inhibitor für SSc und Typ-I-Interferonopathien (FU zum FR). |  | oral (Tablette/Kapsel, geplant) | oral | makrozyklisches NCE (QD-Profil) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3797479 |  | Small Molecule | NME | Neuroscience (CIAS – Cognitive Impairment Associated with Schizophrenia) | Preclinical / Early Development |  | 2032 | Cognitive Impairment Associated with Schizophrenia (CIAS) | Catechol-O-methyltransferase (COMT) inhibitor that modulates dopamine metabolism to improve cognitive processes. | COMT inhibitor targeting dopamine metabolism for CIAS in schizophrenia. | Adults with schizophrenia (CIAS); Parkinson’s disease (CIPD) | Tablet | Oral |  |  |  |  |  | 3A | 0 | AD 2024 |  |  |  |  |  | HIGH: 1 |  |  |  |  |  |  |
| BI 3798489 | BI 3798489 | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Preclinical |  | 2035 | Obesity | NMUR2 agonist for obesity, targeting satiety circuits to reduce food intake and body weight. | NMUR2 agonist peptide for obesity. | Patients with obesity; monthly dosing anticipated | Injectable (subcutaneous) | SC injection |  |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 1 |  |  |  |  |  |  |
| BI 3802876 |  | Recombinant Proteins | NBE | Cardiovascular-Renal-Metabolic (CRM) | Phase I (laufend) | On Track |  | MASH | FAP-verankerter TRAILR2-Agonist (HSC-Ziel). | A FAP-TRAILR2 agonist for MASH. |  | Injectable (IV) | IV | Mammalian |  |  |  |  | 3A | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3804379 |  | Recombinant Proteins | NBE | Cardiovascular-Renal-Metabolic (CRM) | Phase I (laufend) | On Track |  | MASH | Anti-IL11 | An injectable recombinant protein for MASH. |  | Injectable | SC und IV | Mammalian |  |  |  |  | NCY | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3810477 |  | Monoclonal Antibody | NBE | Inflammation & Respiratory | Phase I | Active | 2034 | IPF/PPF | Binds a unique CTGF epitope, preventing cell surface binding and MMP7-mediated CTGF cleavage. | Humanized IgG1 mAb against CTGF for IPF/PPF. |  | Injektionslösung | i.v. und s.c. | Humanisierter IgG1 mit LALA-Fc-Mutation |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3810539 |  | Monoclonal Antibody | NBE | Oncology | Discontinued | Discontinued |  | Triple-Negative Breast Cancer (TNBC); Small Cell Lung Cancer (SCLC) | DLL3 ADC (Antibody-Drug Conjugate). | A DLL3-targeting Antibody-Drug Conjugate (ADC) for Triple-Negative Breast Cancer (TNBC) and Small Cell Lung Cancer (SCLC). |  | Injectable |  |  | Vial |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3810944 |  | Recombinant Proteins | NBE | Oncology | Phase I | On Track | 2032 | Melanoma | Kollagenbindende, MMP9-aktivierte IL-12-Prodrug (ODC). | Systemische ODC-IL12-Prodrug; sentinel indication Melanoma. |  | Injectable |  |  | Vial |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3812465 |  | Recombinant Proteins | NBE | Ophthalmology (CI-DME) | Phase I |  | 2032 | CI-DME | Bispecific FZD4/LRP5-Modulator (Wnt-/Norrin-Mimetikum) to mimic Norrin and activate Wnt/β-catenin signaling, restoring BRB integrity. | Bispecific Wnt-pathway FZD4/LRP5-Modulator for CI-DME to restore BRB integrity. | Patients with chronic diabetic macular edema (CI-DME) | Lösung zur intravitrealen Injektion, 100 mg/mL (Single-dose Vial) + Solvent-Vial | Intravitreal | CHO-exprimiertes rekombinantes bispezifisches Protein (Wnt-Mimetikum) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 1 |  |  |  |  |  |  |
| BI 3814916 | Not yet assigned | Monoclonal Antibody | NBE | Hepatologie (ACLF) | Phase I |  | 2034 | MASH | Anti-TLR4 monoclonal antibody. | Anti-TLR4 monoclonal antibody for Acute-on-Chronic Liver Failure (ACLF). |  | Lösung zur Injektion/Infusion, 150 mg/mL (Vial) | parenteral (i.v. oder s.c.) |  |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 3 |  |  |  |  |  |  |
| BI 3819026 | Anti-LAYN antibody | Monoclonal Antibody | NBE | Oncology | Phase I (FIH) |  | 2035 | Solid Tumors | Humanized IgG1 anti-LAYN antibody targeting LAYN isoforms 1 and 2 to deplete tumor-resident Tregs and enhance anti-tumor immunity, with demonstrated CD16a binding. Afucosylation is not definitively documented. | IgG1 antibody targeting LAYN to deplete tumor Tregs in solid tumors, with demonstrated CD16a binding for enhanced ADCC. | Solid tumors with high Treg infiltration. | Konzentrat zur Herstellung einer Infusionslösung, 150 mg/mL (2 mL-Vial) | intravenöse Infusion | Afucosylated IgG1 (enhanced ADCC) |  |  |  |  | 3A | 0 | AD 2024 |  |  |  |  |  | MED: 1 |  |  |  |  |  |  |
| BI 3820768 |  | T-cell Engager | NBE | Oncology (Solid Tumors) | Preclinical |  | 2031 | 3L Endometrial Cancer (ALPG+) | Bispecific antibody in 2+1 format engaging ALPG on tumor cells and CD3 on T‑cells to induce targeted cytotoxicity and immune activation. | Bispecific TcE targeting ALPG and CD3 for solid tumors | Adults with ALPG+ tumors (initial focus on endometrial cancer) | Injectable (IV infusion); Formulierung nicht offengelegt | Intravenous (to be confirmed) | Bispecific IgG‑like antibody (2+1, Fc knob‑into‑hole) | Vial (reconstitution required) |  |  |  |  | 0 | AD 2024 | Low volume | Low volume |  |  |  | HIGH: 1 |  |  |  | No active submissions; FiH preparation ongoing | US |  |
| BI 3821001 | DcR3-Fc | Recombinant Proteins | NBE | Immunology; IBD | Preclinical/SoD (Ende 2024) |  | 2035 | Ulcerative Colitis | Engineered decoy receptor 3 fused to silenced IgG1 Fc to neutralize TL1A and LIGHT, reducing inflammation and tissue remodeling in IBD. | Fc‑fusion decoy receptor neutralizing TL1A and LIGHT for inflammation control in ulcerative colitis. | Moderate–severe ulcerative colitis. | Injectable (SC or IV) | Injectable | Engineered DcR3‑Fc (reduzierte FasL‑Affinität); dualer TL1A/LIGHT‑Trap |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | MED: 1 |  |  |  |  |  |  |
| BI 3822971 | Not disclosed | T-cell Engager | NBE (ntm) | Oncology | Preclinical |  | 2034 | NSCLC | Bispecific antibody binding LY6K-HLA-A*02:01 on tumor cells and CD3ε on T cells to induce tumor-specific cytotoxicity; Fc engineered for half-life extension and reduced effector function. | Bispecific TcE for NSCLC inducing tumor-specific T‑cell cytotoxicity via LY6K‑HLA/CD3 engagement. |  | Injectable (IV; SC possible later) | IV; SC (possible later) | T‑cell engager (CD3×pMHC) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 3 |  |  |  |  |  |  |
| BI 3906517 |  | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Preclinical | On Track |  | Obesity | Triple-Agonist an GCGR/GIPR/GLP-1R. | Long-acting Triple-Agonist für Adipositas. |  | Injectable | SC (subkutan) | Long-acting Peptid mit Half-Life-Extension (HLE) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3907074 / BI 3907075 / BI 3720590 |  | Gene Therapy | NBE | Oncology | Pre-Clinical | On Track | 2034 | Pancreatic Ductal Adenocarcinoma (PDAC) | Kombination aus KISIMA-Impfkonstrukten (ATP150/152) und VSV-GP onkolytischem Vektor (154). | A complex gene therapy combining multiple proteins (KISIMA) and an oncolytic virus for Pancreatic Ductal Adenocarcinoma (PDAC). |  | Injectable |  | Viral (VSV-GP) + Impfplattform (KISIMA®) | Vial |  |  |  | NCY | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 3923948 | Not disclosed | Gene Therapy | NME | Oncology | Pre-Clinical (IMPD submitted September 2025) | On Track | 2034 | Triple-Negative Breast Cancer (TNBC) | VSV-GP oncolytic virus with GSDME-IL12 payload - combines productive tumor cell infection and oncolysis (VSV-GP platform) with GSDME-mediated immunogenic cell death and IL-12-driven CD8+ T-cell activation to 'heat up' the tumor microenvironment. | Oncolytic virus platform for triple-negative breast cancer. VSV-GP vector carrying GSDME and IL-12 transgenes for combined oncolysis and immune activation. | Patients with triple-negative breast cancer | Solution for injection/infusion | To be determined (likely intratumoral or intravenous) |  |  |  |  |  |  |  |  |  |  |  |  |  | MED: 2 |  |  |  |  |  |  |
| BI 3940749 | Not disclosed | Small Molecule | NME | Oncology | Pre-Clinical (FIH Q2/2026) | On Track | 2031 | Solid tumors with KRAS drivers (CRC, NSCLC, PDAC) | KRAS multi-degrader (PROTAC) - uses CRBN-mediated ubiquitination to induce proteasomal degradation of KRAS proteins. Pan-KRAS approach targeting multiple KRAS mutations through targeted protein degradation via E3 ligase CRBN. | Pan-KRAS PROTAC degrader for solid tumors with KRAS drivers (PDAC, NSCLC, CRC). Oral small molecule using CRBN E3 ligase for protein degradation. | Patients with KRAS-driven solid tumors including pancreatic cancer, non-small cell lung cancer, and colorectal cancer | Tablet (oral formulation using spray-dried dispersion or CAPS technology) | Oral | Spray Dried Dispersion (SDD) or CAPS (pH-dependent solubility) |  |  |  |  |  |  |  |  |  | ING (development) |  |  | HIGH: 1 |  |  |  |  |  |  |
| BI 3968621 | Not disclosed | Small Molecule | NME | Oncology | Preclinical |  | 2035 | RCC | PROTAC targeting HPK1 for proteasomal degradation via CRBN E3 ligase recruitment; enhances T/B/DC activation to boost anti-tumor immunity. | Oral PROTAC degrading HPK1 to boost immune activation for RCC; preclinical development. |  | Oral tablet | Oral | Targeted protein degrader (CRBN‑recruiting PROTAC) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 2 |  |  |  |  |  |  |
| BI 3972080 | CT‑155 | Prescription Digital Therapeutic (SaMD/PDT) | DTx | Mental Health / CNS (CREA) | Phase III – pivotal CONVOKE abgeschlossen; primärer Endpunkt erreicht |  | 2026 | Experiential Negative Symptoms in Schizophrenia (XNS SCZ) | Smartphone‑based PDT delivering evidence‑based psychosocial interventions (adaptive goal setting, cognitive restructuring, behavioral activation, social skills, positive‑affect training). Targets defeatist beliefs and promotes real‑world engagement to reduce experiential negative symptoms as an adjunct to standard‑of‑care antipsychotics. | Digital therapeutic for negative symptoms in schizophrenia | Adults with schizophrenia on stable antipsychotic therapy, experiencing moderate–severe experiential negative symptoms | Software / Mobile App (SaMD) | Digital (smartphone‑delivered) | SaMD (mobile smartphone application) |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 2 | MED: 1 |  | XNS_SCZ: 1 designation | Targeted first submission: Jan 23, 2026 | US |  |
| BI 4018711 | CT‑156 (working title) | Prescription Digital Therapeutic (SaMD/PDT) | DTx (SaMD) | Schizophrenia / Neuroscience (TA CREA) | Phase II |  | 2028 | Functional Impairment in Schizophrenia (FI SCZ) | Software‑based prescription digital therapeutic designed to improve functional outcomes in schizophrenia through structured behavioral interventions delivered via a mobile platform. | Digital therapeutic to improve functional outcomes in schizophrenia via mobile behavioral interventions | Patients with schizophrenia experiencing functional impairment | Software application (mobile/connected) | Digital (software‑delivered intervention) | SaMD (mobile smartphone application) | Not applicable (digital product) |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | HIGH: 3 |  |  |  | No active submission | US |  |
| BI 4041979 | T3P-Y058-739 (Not disclosed) | Gene Therapy | NME | Oncology / Immuno-Oncology | Phase I | On Track | 2032 | Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma | Dual innate immunity activator (cGAS/RIG-I) via genetically modified Yersinia enterocolitica - bacterial vector immunotherapy that selectively colonizes tumors and delivers immune modulators via Type III secretion system. Activates both cGAS → cGAMP → STING pathway and RIG-I → MAVS/IRF3 signaling, inducing strong Type I Interferon signature to 'heat up' tumor microenvironment. | Bacterial vector immunotherapy (attenuated Y. enterocolitica) activating innate immunity via dual cGAS/RIG-I pathways. Phase I evaluating intratumoral and intravenous routes as monotherapy and in combination with PD-1 inhibitors in HNSCC and melanoma. | Patients with advanced solid tumors (HNSCC, melanoma) in monotherapy or combination with PD-1 inhibitors | Live bacterial suspension (attenuated Yersinia enterocolitica) | Intratumoral (IT) and Intravenous (IV) | Bacterial vector immunotherapy using Type III secretion system for tumor-selective delivery |  |  |  |  |  |  |  |  |  |  |  |  | HIGH: 4 ¦ MED: 2 |  |  | Development: 2 designations |  |  |  |
| BI 456906 | Survodutide | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase III | Delayed | 2027 | Obesity | A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. | A GCGR/GLP-1 receptor dual agonist for people living with overweight or obesity, and for those with MASH. | People living with overweight or obesity (BMI ≥ 27 kg/m²) and people living with MASH. | Fertigspritze/Autoinjektor (in Entwicklung) | Subkutan | Synthese via SPPS (Peptid) | PEN device | Halted | CMC | DS: PPG=halted ¦ DP: - |  | 86 | AD 2024 |  |  | PPG (halted) | Thermo Fisher; ING | Nemera (PEN/Primary) | HIGH: 2 | CRIT: 2 |  | Obesity: 2 designations |  |  |  |
| BI 456906_GEN2 | Survodutide 2nd Gen | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2029 | Obesity | A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. | Second generation drug substance formulation of Survodutide. New 'formulation 2.0' development. | People living with overweight or obesity (BMI ≥ 27 kg/m²) | Fertigspritze/Autoinjektor | Subkutan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 456906_MASH1 | Survodutide | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) | Phase III | Delayed | 2028 | MASH F2/F3 | A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. | Line extension of Survodutide for MASH F2/F3. Shares same NME development path, approximately one year behind obesity indication. | People living with MASH F2/F3 | Fertigspritze/Autoinjektor | Subkutan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 456906_MASH2 | Survodutide | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2030 | MASH cF4 | A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. | Line extension of Survodutide for compensated cirrhosis due to MASH (cF4 stage). | People living with MASH cF4 | Fertigspritze/Autoinjektor | Subkutan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 456906_PED | Survodutide PED | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) | Pre-Clinical |  | 2031 | Pediatric Obesity; MASH | A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. | Pediatric line extension of Survodutide for obesity and MASH in pediatric populations. | Pediatric patients with overweight/obesity or MASH | Pediatric formulation | Subkutan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 456906_PEN | Survodutide PEN | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) | Development | On Track | 2028 | Obesity | A novel glucagon receptor (GCGR) and GLP-1 receptor dual agonist. | PEN device line extension of Survodutide for obesity. Nemera volume ramp-up scenario is key focus. | People living with overweight or obesity (BMI ≥ 27 kg/m²) | PEN device | Subkutan |  | PEN device |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 655130 | Spesolimab | Monoclonal Antibody | NBE | Immunology; Neutrophilic Dermatoses | Marketed (GPP flares) |  | 2027 | Pyoderma Gangrenosum (PG) | Humanized IgG1 monoclonal antibody antagonizing IL-36 receptor (IL-36R), blocking IL-36α, IL-36β, and IL-36γ signaling. | Anti-IL-36R monoclonal antibody approved for GPP flares, investigational for pyoderma gangrenosum; IV for flares, SC for prevention. | Adults with active PG lesions. | IV for acute flare; SC for long-term prevention | Injectable |  | Vial; Prefilled syringe |  |  |  |  | 0 | AD 2024 |  |  |  |  |  | MED: 2 |  |  | Systemic Sclerosis (SSc): 1 designation |  |  |  |
| BI 685509 | Avenciguat | Small Molecule | NME | Immunology (Systemische Sklerose) und CRM/Nephrologie (Glomerulonephritiden) | Phase II (SSc) and Phase III (GN) | On Track | 2028 | Glomerulonephritis (GN) | A soluble guanylate cyclase (sGC) activator. | An sGC activator for fibrotic and vascular diseases, with active development in Systemic Sclerosis (Phase II) and Glomerulonephritis (Phase III). |  | Tablet | Oral | Direct Compression | Blister; Bottle | Ongoing |  | DS: ING=transfer_ongoing ¦ DP: ING_SoL=transfer_ongoing | 3B | 0 | AD 2024 | Medium (1 - 10 tn) | High (> 100 mio PCS) | ING @Ingelheim (ongoing) | ING_SoL @Ingelheim (ongoing) |  |  |  |  | SSc: 1 designation |  |  |  |
| BI 685509_PED | Avenciguat PED | Small Molecule |  | Immunology | Pre-Clinical |  | 2034 | Systemic Sclerosis Pediatric | A soluble guanylate cyclase (sGC) activator. | Pediatric line extension of Avenciguat for Systemic Sclerosis in pediatric populations. | Pediatric patients with Systemic Sclerosis | Pediatric formulation | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 685509_SSC | Avenciguat | Small Molecule |  | Immunology | Phase II | On Track | 2030 | Systemic Sclerosis | A soluble guanylate cyclase (sGC) activator. | Line extension of Avenciguat for Systemic Sclerosis. sGC activator for fibrotic and vascular disease. Fast Track Designation granted. | Patients with Systemic Sclerosis | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | SSc: 1 designation |  |  |  |
| BI 690517 | Vicadrostat | Small Molecule | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase III | On Track | 2028 | Chronic Kidney Disease (CKD) | A novel, selective, and potent aldosterone synthase inhibitor (ASi). | An aldosterone synthase inhibitor used in combination with empagliflozin for cardiovascular and renal disease. |  | Tablet | Oral | Twin Screw | Blister; Bottle | Ongoing |  | DS: ING=transfer_ongoing ¦ DP: ING_SoL=transfer_ongoing | 3A | 0 | AD 2024 | High (> 10 tn) | High (> 100 million PCS) | ING @Ingelheim (ongoing) | ING_SoL @Ingelheim (ongoing) |  |  |  |  |  |  |  |  |
| BI 690517_CVRR | Vicadrostat + empagliflozin | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2031 | CVRR | A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor. | Line extension of Vicadrostat in combination with empagliflozin for cardiovascular-renal risk reduction. | Patients at high cardiovascular-renal risk | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 690517_HFPEF | Vicadrostat + empagliflozin | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) | Phase III | On Track | 2029 | HFpEF | A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor. | Line extension of Vicadrostat in combination with empagliflozin for heart failure with preserved ejection fraction. Developed in parallel with CKD indication. | Patients with HFpEF on top of standard of care | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 690517_HFREF | Vicadrostat + empagliflozin | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2030 | HFrEF | A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor. | Line extension of Vicadrostat in combination with empagliflozin for heart failure with reduced ejection fraction. | Patients with HFrEF on top of standard of care | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 690517_PED | Vicadrostat + empagliflozin PED | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) | Pre-Clinical |  | 2035 | CKD Pediatric | A novel, selective, and potent aldosterone synthase inhibitor (ASi) in combination with SGLT2 inhibitor. | Pediatric line extension of Vicadrostat in combination with empagliflozin for chronic kidney disease in pediatric populations. | Pediatric patients with CKD | Pediatric formulation | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 706321 |  | Small Molecule | NME | Immunology | Discontinued | Discontinued |  | Crohn's Disease (CD) | RIPK2 inhibitor. | A RIPK2 inhibitor targeting the NOD signaling pathway involved in innate immunity and inflammation in IBD. |  | Tablet | Oral |  | Blister; Bottle |  |  |  | 3B | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 754091 | Ezabenlimab | Monoclonal Antibody | NBE | Oncology | Phase I/II (laufende Kombinationsprogramme) | On Track |  | IV formulation for use in Oncology combinations. | A humanized programmed cell death 1 (PD-1)-targeting monoclonal antibody. | PD-1 antibody as a combination backbone (e.g., with TcEs, STING-Ago., SIRPα-Antag., MDM2-Inhib.). |  | Injectable | Intravenous (IV) | Mammalian | Vial |  |  |  | 3A | 0 | AD 2024 | Low (6 - 15 12k runs) | Low (1 - 10 million PCS) | Fremont @Fremont (ongoing) | BC_F113 @Biberach (ongoing) |  |  |  |  |  |  |  |  |
| BI 754132 | Not disclosed | Small Molecule | NME | Eye Health | Discontinued | Discontinued |  | Geographic Atrophy (GA) | TrkB activator. | A TrkB activator designed to have neuroprotective effects in the retina for conditions like Geographic Atrophy (GA), administered via intravitreal injection. |  | Lösung zur intravitrealen Injektion | Intravitreal |  |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764198 | Not disclosed | Small Molecule | NME | Nephrology / Renal | Phase II | On Track | 2031 | Focal Segmental Glomerulosclerosis (FSGS) | TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6. | TRPC6 inhibitor for renal diseases, primarily targeting FSGS (Focal Segmental Glomerulosclerosis). | Patients with FSGS and other proteinuric kidney diseases | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764198_DMD | Not disclosed | Small Molecule |  | Neuromuscular Disorders |  |  | 2032 | Duchenne Muscular Dystrophy | TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6. | Line extension of TRPC6 inhibitor for Duchenne Muscular Dystrophy. | Patients with Duchenne Muscular Dystrophy | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764198_PED | Not disclosed | Small Molecule |  | Nephrology / Renal | Pre-Clinical |  | 2035 | FSGS Pediatric | TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6. | Pediatric line extension of TRPC6 inhibitor for FSGS in pediatric populations. | Pediatric patients with FSGS | Pediatric formulation | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764198_PODO | Not disclosed | Small Molecule |  | Nephrology / Renal |  |  | 2034 | Podocytopathies | TRPC6 inhibitor - inhibits the Transient Receptor Potential Cation Channel Subfamily C Member 6. | Line extension of TRPC6 inhibitor for podocyte-related kidney diseases. | Patients with podocytopathies | Tablet | Oral |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764524 | Not disclosed | Monoclonal Antibody | NME | Ophthalmology | Phase II | On Track | 2031 | Diabetic Retinopathy (DR) | Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology. | Anti-Sema3A antibody for retinal diseases, primarily targeting Diabetic Retinopathy. | Patients with Diabetic Retinopathy | Solution for injection | Intravitreal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764524_DME | Not disclosed | Monoclonal Antibody |  | Ophthalmology |  |  | 2032 | CI-DME | Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology. | Line extension of anti-Sema3A antibody for center-involved diabetic macular edema. | Patients with CI-DME | Solution for injection | Intravitreal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764524_IRVO | Not disclosed | Monoclonal Antibody |  | Ophthalmology |  |  | 2032 | iRVO | Anti-Semaphorin 3A (anti-Sema3A) antibody - targets SEMA3A, a protein implicated in retinal vascular and neuronal pathology. | Line extension of anti-Sema3A antibody for macular edema following retinal vein occlusion. | Patients with iRVO | Solution for injection | Intravitreal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764532 | Obrixtamig | T-cell Engager | NME | Oncology | Phase II | On Track | 2027 | Extra-pulmonale neuroendokrine Karzinome (2L epNEC) | Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung. | Bispezifischer Antikörper für neuroendokrine Karzinome. Lead indication: 2L epNEC als Monotherapie. | Patienten mit DLL3-positiven neuroendokrinen Karzinomen | Pulver für Lösung zur Infusion | Intravenös und subkutan |  | Glasvial (30 mg/Vial) | DS abgeschlossen, DP geplant Q4/2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | US; Germany; Japan; China |  |
| BI 764532_EPNEC | Obrixtamig | T-cell Engager |  | Oncology | Phase Ib/III | On Track | 2029 | Extra-pulmonale neuroendokrine Karzinome (First-Line) | Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung. | Line extension of Obrixtamig for first-line epNEC. Combination therapy with Pt/Etoposid (Dareon™-7). | Patients with extra-pulmonary neuroendocrine carcinomas, first-line treatment | Pulver für Lösung zur Infusion | Intravenös und subkutan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 764532_SCLC | Obrixtamig | T-cell Engager |  | Oncology | Phase III | On Track | 2029 | Extensive-Stage Small Cell Lung Cancer (First-Line) | Bispezifischer DLL3/CD3 T-Zell-Engager, der DLL3 auf Tumorzellen und CD3 auf T-Zellen bindet zur gezielten Immunaktivierung. | Line extension of Obrixtamig for first-line ES-SCLC. Combination therapy with Pt/Etoposid + Immunotherapy (Dareon™-9). | Patients with extensive-stage small cell lung cancer, first-line treatment | Pulver für Lösung zur Infusion | Intravenös und subkutan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 765049 | Not disclosed | T-cell Engager | NME | Oncology | Phase I | On Track | 2030 | Colorectal Cancer (CRC) | B7-H6/CD3 bispecific T-cell engager - binds B7-H6 on tumor cells and CD3 on T-cells to activate immune response against cancer cells. | B7-H6/CD3 bispecific T-cell engager for colorectal cancer. First-in-human Phase I as monotherapy and in combination with PD-1 inhibitor ezabenlimab. | Patients with advanced colorectal cancer and other gastrointestinal malignancies | Solution for infusion | Intravenous |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 765128 |  | Monoclonal Antibody | NBE | Eye Health | Phase I/II (PARTRIDGE 1451-0001) | Discontinued | 2030 | Diabetic Retinopathy (DR) | Anti-NRP1 antibody. | Anti-NRP1 mAb for diabetic macular ischemia (DMI). | Patients with diabetic retinopathy | Injectable | Intravitreal | Mammalian | IVT_PFS (Intravitreal Pre-filled Syringe) |  |  |  | 2 | 0 | AD 2024 | Very Low (<5 12k runs) | Very Low (<1 million PCS) | Rentschler @N/A (qualified) | Vetter @N/A (qualified) |  |  |  |  |  |  |  |  |
| BI 765179 | Not disclosed | Monoclonal Antibody | NME | Oncology | Phase Ib | On Track | 2031 | Head and Neck Squamous Cell Carcinoma (HNSCC), First-Line PD-L1+ | CD137-FAP bispecific agonist antibody - provides tumor-restricted CD137 activation through cancer-associated fibroblast (CAF) targeting via FAP. | CD137-FAP bispecific agonist antibody for head and neck squamous cell carcinoma. Phase Ib in combination with pembrolizumab for first-line PD-L1+ HNSCC. | Patients with PD-L1+ head and neck squamous cell carcinoma, first-line treatment | Solution for infusion | Intravenous |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 765243 |  | Recombinant Proteins | NBE | Eye Health | Pre-Clinical | Discontinued |  | Wet AMD (nAMD) | TrkB/anti-VEGF (bispecific). | Bispecific protein targeting TrkB and VEGF for wet AMD |  |  |  |  |  |  |  |  |  | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 765250 |  | Monoclonal Antibody | NBE | Immunology | Phase I (SRD abgeschlossen; MRD laufend/PoCP-Vorbereitung) | On Track |  | Systemic Sclerosis (SSc) | PD-1 agonist. | A PD-1 agonist antibody for immunological conditions like Systemic Sclerosis (SSc). |  | IV und SC | Intravenös; Subkutan | Mammalian | Bulk_PFS (Bulk Pre-filled Syringe) |  |  |  | 3A | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 765423 |  | Monoclonal Antibody | NBE | Respiratory | Phase I | On Track | 2034 | Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPFr) | IL-11 blockade by binding to soluble IL-11 and preventing the IL-11/IL-11R interaction. | An anti-IL11 antibody designed to block the IL-11 cytokine implicated in fibrotic lung diseases. |  | Injectable | Injectable (SFInj) | Mammalian | Bulk_PFS (Bulk Pre-filled Syringe) |  |  |  | 2 | 0 | AD 2024 |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 765845 | Not disclosed (internal: G5 MYDGF) | Recombinant Proteins | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase II | On Track | 2031 | ST-Elevation Myocardial Infarction (STEMI) | Myeloid-Derived Growth Factor (MYDGF) - recombinant protein designed for tissue protection and cardiac repair post-STEMI. Reduces cardiomyocyte apoptosis from reperfusion injury and promotes angiogenesis for improved cardiac regeneration. | Recombinant MYDGF protein for acute STEMI treatment. Single IV bolus in catheterization lab during primary PCI to reduce reperfusion injury. | STEMI patients with complete or near-complete coronary occlusion undergoing primary PCI | Solution for infusion (acute bolus) | Intravenous (Single-Dose in catheterization lab) |  |  |  |  |  |  |  |  |  |  |  |  |  | HIGH: 1 |  |  |  |  |  |  |
| BI 770371 | Not disclosed | Recombinant Proteins | NME | Oncology | Phase I/II | On Track | 2032 | Head and Neck Squamous Cell Carcinoma (HNSCC) | SIRPα antagonist - blocks the Signal Regulatory Protein alpha (SIRPα) to enhance macrophage-mediated tumor cell phagocytosis. | SIRPα antagonist for oncology, primarily targeting Head and Neck Squamous Cell Carcinoma. | Patients with HNSCC | Solution for infusion | Intravenous |  | Vial (500 mg/vial, 50 mg/mL) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 770371_MASH | Not disclosed | Recombinant Proteins |  | Hepatology / CRM |  |  | 2034 | MASH | SIRPα antagonist - blocks the Signal Regulatory Protein alpha (SIRPα) to enhance macrophage-mediated phagocytosis and reduce inflammation. | Line extension of SIRPα antagonist for MASH, targeting inflammatory pathways in metabolic liver disease. | Patients with MASH | Solution for infusion | Intravenous |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| BI 771716 | Not disclosed | Monoclonal Antibody | NME | Ophthalmology / Retinal Health | Phase II | On Track | 2030 | Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) | Anti-C3/C3b antibody fragment (scFv) - highly specific single-chain variable fragment targeting C3 and C3b, inhibiting complement activation via all three pathways (classical, lectin, and alternative). | Anti-C3 antibody fragment (scFv) for Geographic Atrophy secondary to AMD. Intravitreal injection showing >90% reduction of free C3 in aqueous humor. Phase II VERDANT study active comparing q4w and q8w regimens vs pegcetacoplan. | Patients with Geographic Atrophy secondary to AMD | Solution for injection (single-dose vial, 150 mg/mL, 150 mg/vial) | Intravitreal injection (IVT) | Single-chain variable fragment (scFv) format | Single-dose vial (current development; PFS platform under portfolio-wide evaluation) |  |  |  |  |  |  |  |  | RCV @Biberach/Vienna network (active) |  |  | MED: 2 |  |  | None |  |  |  |
| BI XXXXX | Tenecteplase | Recombinant Proteins | NME | Neurology / Stroke | Phase III | On Track | 2029 | Acute Ischemic Stroke (AIS) in extended time window (4.5-24h) | Tissue Plasminogen Activator - recombinant fibrin-specific thrombolytic agent that converts plasminogen to plasmin. | Tissue plasminogen activator for acute ischemic stroke in extended time window (4.5-24h). Single-bolus administration offers practical advantage over alteplase. | Patients with acute ischemic stroke, including basilar artery occlusion (BAO) up to 24 hours | Solution for injection | Intravenous (single bolus) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | AIS: 1 designation |  |  |  |
